If you are interested in participating in a clinical trial, please contact the St. John Clinical Research Institute at 918-744-3068 or email@example.com.
The Clinical Research Institute coordinates and conducts a variety of clinical trials, including ones for the following therapeutic areas:
- Cardiovascular diseases
- Genetic diseases
- Healthy volunteers
- Hepatology (liver, pancreas and gall bladder)
- Infections and infectious diseases
- Internal medicine
- Nutrition and weight loss
- Orthopedics and orthopedic surgery
- Pulmonary and respiratory diseases
- Trauma (emergency, injury and surgery)
In a clinical trial, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or changes to participants' behavior, such as diet. Trials may compare a new medical approach to a standard one that is already available, to a placebo that contains no active ingredients or to no intervention.
When a new product or approach is being studied, it is not usually known whether it will be helpful, harmful or no different than available alternatives (including no intervention). The investigators try to determine the safety and effectiveness of the intervention by measuring certain outcomes in the participants.
The following clinical trials by St. John Health System are open for patient enrollment. For a list of all active trials, click here.
St. John Heart Institute
- ECLIPSE – A study to evaluate the treatment strategies for severe coronary artery calcification: orbital atherectomy vs. conventional angioplasty technique prior to implantation of drug-eluting stents. The divide is the Diamondback 360® Coronary Orbital Atherectomy System (OAS) 1.25 mm classic crown.
- GEMINI – A drug study to compare the safety of rivaroxaban with acetylsalicylic acid, in addition to either clopidogrel or ticagrelor therapy for acute coronary syndrome.
- GRAFTMASTER – A device study to assess a coronary stent graft system for the treatment of free perforations defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts more than 2.75 mm in diameter.
- LOW-RISK TAVR – A device study to measure the feasibilty of transcatheter aortic valve replacement in low-risk patients with symptomatic, severe aortic stenosis. This study is currently allowing only enrollment in the bicuspid arm.
- PIONEER HF – A drug study to assess the effect of in-hospital initiation of sacubitril/valsartan compared with enalapril.
- TAVR – A device study to measure the quality of care for patients receiving transcatheter valve therapy.
Click here to visit the St. John Heart Institute Web page.
St. John Neuroscience Institute
- CORDIS ENTERPRISE HUD – A device study to assess a vascular reconstruction system.
- DYSTONIA HUD – A device study required by the U.S. Food & Drug Administration to allow patients to undergo deep brain stimulation surgery for the treatment of dystonia.
- LVIS HUD – A device study to evaluate the safety and benefits of the low-profile visualized intraluminal support (LVIS and LVIS Jr.) devices from MicroVention Inc. when used to facilitate endovascular coiling of unruptured, wide-necked, intracranial aneurysms with bare platinum embolization coils.
- WINGSPAN HUD – A device study to assess the Wingspan Stent System with Gateway PTA Balloon Catheter.
Click here to visit the St. John Neuroscience Institute Web page.
St. John Heyman Stroke Center
- ARAMIS – A study to address real-world anticoagulant management issues in stroke registry.
- CREST 2 – A study on carotid revascularization and medical management for asymptomatic carotid stenosis.
- MaRISS – A study to evaluate treatment options for patients with mild and rapidly improving stroke symptoms.
Click here to visit the St. John Heyman Stroke Center Web page.
St. John Trauma Center
- ARDS – A Phase I study comparing outcomes in trauma-specific refractory acute respiratory distress syndrome (ARDS) using a high-frequency oscillatory ventilator versus “proning” as a salvage protocol.
- RE-VERSal – A Phase III, case series study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5g idarucizumab (BI 655075) in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.
Click here to visit the St. John Trauma Center Web page.
St. John Breast Center
- MAMMOGRAM CAD* – An observational study to improve the detection of breast cancer using a novel computer-assisted diagnosis system and analytic approach applied to mammography.
Click here to visit the St. John Breast Center Web page.
*These clinical trials are conducted in collaboration with the national Ascension Clinical Research Institute, which brings together research sites at Ascension ministries across the country to share resources and expertise.